GLP-1 Agonists and Atherosclerosis
GLP-1 Cardiovascular
20% MACE reduction
Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in the SELECT trial of 17,604 patients with obesity and established cardiovascular disease.
Lincoff et al., NEJM, 2023
Lincoff et al., NEJM, 2023
View as imageThe cardiovascular outcome trials for GLP-1 receptor agonists were designed to prove these drugs do not cause heart attacks. Instead, they proved the opposite: GLP-1 receptor agonists actively prevent them. Across six major randomized controlled trials enrolling over 60,000 patients, liraglutide, semaglutide, dulaglutide, and albiglutide each reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The consistency of this effect across multiple drugs in the same class, and across patient populations with and without diabetes, points to a mechanism beyond glucose control or weight loss. That mechanism appears to be direct antiatherosclerotic action. For a broader view of GLP-1 cardiovascular benefits, see our pillar article on GLP-1 drugs and heart disease.
Key Takeaways
- Semaglutide 2.4 mg reduced MACE by 20% (HR 0.80) in 17,604 patients with obesity and CVD but without diabetes in the SELECT trial (Lincoff et al., 2023)
- Liraglutide reduced MACE by 13% (HR 0.87, p=0.01 for superiority) and cardiovascular death by 22% in the 9,340-patient LEADER trial (Marso et al., 2016)
- A meta-analysis of seven CVOTs found GLP-1RAs reduced MACE by 12% (HR 0.88), all-cause mortality by 12%, and hospital admission for heart failure by 9% (Kristensen et al., 2019)
- GLP-1RAs reduce atherosclerosis through at least five mechanisms: endothelial protection, anti-inflammatory signaling, foam cell inhibition, smooth muscle proliferation suppression, and plaque stabilization (Park et al., 2024)
- Liraglutide decreased carotid intima-media thickness from 1.19 mm to 0.94 mm over 8 months in a pilot study of patients with type 2 diabetes (Rizzo et al., 2014)
- Cardiovascular benefits appear early, with event curves separating within 12-18 months of treatment initiation
The Cardiovascular Outcome Trial Evidence
LEADER: Liraglutide Sets the Standard
The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to liraglutide 1.8 mg or placebo daily for a median of 3.8 years. Marso et al. (2016) reported that the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 13.0% of the liraglutide group versus 14.9% of the placebo group (HR 0.87; 95% CI 0.78-0.97; p=0.01 for superiority).[1]
The reduction in cardiovascular death was particularly striking: 4.7% versus 6.0% (HR 0.78; 95% CI 0.66-0.93; p=0.007). All-cause mortality was also lower with liraglutide (8.2% vs 9.6%). This was the first GLP-1 receptor agonist trial to demonstrate cardiovascular superiority, and the mortality reduction signaled that the benefit extended beyond preventing nonfatal events.
SUSTAIN-6 and SELECT: Semaglutide Across Populations
SUSTAIN-6 tested subcutaneous semaglutide (0.5 mg and 1.0 mg weekly) in 3,297 patients with type 2 diabetes at high cardiovascular risk. Marso et al. (2016) found that the primary outcome occurred in 6.6% of the semaglutide group versus 8.9% of the placebo group (HR 0.74; 95% CI 0.58-0.95; p<0.001 for noninferiority).[2] The 26% reduction in MACE was the largest observed in any GLP-1RA trial, driven primarily by a 39% reduction in nonfatal stroke (HR 0.61; 95% CI 0.38-0.99).
The SELECT trial then asked whether semaglutide's cardiovascular benefit extended to patients without diabetes. Lincoff et al. (2023) enrolled 17,604 patients aged 45 or older with established cardiovascular disease, a BMI of 27 or greater, and no diabetes. Semaglutide 2.4 mg weekly reduced the primary endpoint by 20% (6.5% vs 8.0%; HR 0.80; 95% CI 0.72-0.90; p<0.001) over a mean follow-up of 39.8 months.[3] SELECT was paradigm-shifting because it demonstrated that GLP-1RA cardiovascular protection is not contingent on glucose lowering. Patients without diabetes, who received no glycemic benefit, still had fewer heart attacks, strokes, and cardiovascular deaths.
REWIND: Dulaglutide in Lower-Risk Populations
The REWIND trial enrolled 9,901 patients with type 2 diabetes, of whom only 31% had established cardiovascular disease at baseline (compared to 73-83% in LEADER and SUSTAIN-6). Despite this lower-risk population, dulaglutide 1.5 mg weekly reduced MACE by 12% (HR 0.88; 95% CI 0.79-0.99; p=0.026) over a median 5.4 years of follow-up.[4] REWIND demonstrated that GLP-1RA cardiovascular protection extends to primary prevention, not just secondary prevention in patients who have already had a cardiovascular event.
The Meta-Analysis: Class-Wide Effect
Kristensen et al. (2019) pooled data from seven cardiovascular outcome trials of GLP-1 receptor agonists (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, and PIONEER-6), comprising 56,004 patients. GLP-1RAs reduced MACE by 12% (HR 0.88; 95% CI 0.82-0.94), all-cause mortality by 12% (HR 0.88; 95% CI 0.83-0.95), and hospital admission for heart failure by 9% (HR 0.91; 95% CI 0.83-0.99).[5] The MACE reduction was driven by reductions in both atherosclerotic events (HR 0.86) and cardiovascular death. The consistency across multiple different GLP-1RA molecules supports a class-wide mechanism rather than molecule-specific effects.
Direct Antiatherosclerotic Mechanisms
Park et al. (2024) published a comprehensive mechanistic review in the American Journal of Physiology, cataloguing how GLP-1 receptor agonists interfere with atherosclerosis at each stage of plaque development.[6] The effects operate through at least five distinct pathways:
Endothelial Protection
Atherosclerosis begins with endothelial dysfunction. The endothelial lining of blood vessels loses its ability to produce nitric oxide, becomes permeable to lipoproteins, and starts expressing adhesion molecules that recruit inflammatory cells. GLP-1 receptors are expressed on endothelial cells, and GLP-1RA activation promotes angiogenesis, inhibits oxidative stress, and preserves endothelial nitric oxide synthase (eNOS) activity. In cell culture and animal models, liraglutide and exenatide prevent the endothelial dysfunction induced by high glucose, oxidized LDL, and inflammatory cytokines.
Anti-Inflammatory Signaling
Inflammation drives every stage of atherosclerosis, from initial lipid deposition through plaque rupture. GLP-1RAs suppress NF-kB activation, the master transcription factor for inflammatory gene expression. This reduces production of TNF-alpha, IL-6, and IL-1-beta, the cytokines that amplify vascular inflammation. GLP-1RAs also inhibit the NLRP3 inflammasome, a cellular complex that processes IL-1-beta into its active form. In perivascular adipose tissue, GLP-1 signaling reduces inflammasome activation through a SIRT1/NOX4 pathway that promotes mitophagy (clearance of damaged mitochondria) and reduces reactive oxygen species production. For a dedicated analysis of these anti-inflammatory mechanisms, see how GLP-1 drugs reduce cardiovascular inflammation.
Monocyte Recruitment and Foam Cell Formation
Monocytes that migrate into the arterial wall and engulf oxidized LDL become foam cells, the lipid-laden macrophages that form the core of atherosclerotic plaques. GLP-1RAs interfere with this process at multiple points. They reduce monocyte adhesion to the endothelium by downregulating adhesion molecule expression. They inhibit monocyte migration into the subendothelial space. And they directly block foam cell formation by downregulating ACAT1, the enzyme that esterifies cholesterol for storage in macrophage lipid droplets. Exenatide specifically reduces macrophage uptake of oxidized LDL through GLP-1 receptor activation, preventing the lipid accumulation that converts macrophages into foam cells.
Macrophage Polarization
Macrophages in atherosclerotic plaques exist on a spectrum between pro-inflammatory M1 and anti-inflammatory M2 phenotypes. Vulnerable plaques contain predominantly M1 macrophages, which secrete tissue-degrading enzymes and inflammatory cytokines. GLP-1RAs promote polarization toward the M2 phenotype through effects on CCAAT/enhancer-binding protein beta, MAPK, and NF-kB signaling. This shift stabilizes plaques by reducing matrix metalloproteinase production and increasing collagen synthesis, creating a thicker, more stable fibrous cap.
Vascular Smooth Muscle Cell Regulation
Vascular smooth muscle cell proliferation and migration contribute to plaque growth and arterial narrowing. GLP-1 receptor activation in smooth muscle cells increases intracellular cAMP, which reduces NF-kB and MAPK signaling, two pro-proliferative pathways. This limits intimal thickening while potentially preserving the smooth muscle cells that contribute to fibrous cap stability.
Imaging Evidence: Plaque Regression and Carotid Remodeling
The mechanistic data predict that GLP-1RAs should slow or reverse measurable atherosclerosis. Rizzo et al. (2014) tested this in a prospective pilot study of patients with type 2 diabetes treated with liraglutide for 8 months. Carotid intima-media thickness (CIMT), an ultrasound-based measure of subclinical atherosclerosis, decreased from 1.19 mm to 0.94 mm, a 21% reduction.[7] This reduction exceeded what would be expected from glucose or lipid improvements alone, consistent with a direct antiatherosclerotic effect.
More recent data from Gitto et al. (2026) examined coronary plaque regression in diabetic patients treated with GLP-1 receptor agonists after percutaneous coronary intervention. Using intravascular imaging, they found that GLP-1RA-treated patients showed greater plaque regression compared to those on standard therapy.[8]
These imaging findings remain limited by small sample sizes and short follow-up. A definitive imaging trial with a GLP-1RA, using serial coronary CT angiography or intravascular ultrasound with adequate power and duration, has not been completed. The cardiovascular outcome trial data showing MACE reduction provides the strongest evidence for clinical benefit, while the imaging data provides mechanistic corroboration.
Beyond Glucose and Weight: Why Direct Vascular Effects Matter
A critical question in the GLP-1RA cardiovascular field is how much of the benefit comes from improved metabolic parameters (glucose, weight, blood pressure, lipids) versus direct antiatherosclerotic effects. The SELECT trial partially answered this: patients without diabetes received no glycemic benefit, yet still had a 20% MACE reduction. Weight loss in SELECT was meaningful (mean 9.4% at 2 years), but statistical modeling suggests the cardiovascular benefit exceeds what weight loss alone would predict.
The timeline of benefit provides additional evidence for direct vascular effects. In the major CVOTs, event curves for GLP-1RA and placebo groups begin separating within 12-18 months. Weight loss, blood pressure reduction, and lipid improvements also begin early but accumulate gradually over years. An antiatherosclerotic mechanism, stabilizing existing vulnerable plaques and reducing the inflammatory milieu that triggers plaque rupture, would explain the relatively rapid onset of cardiovascular protection.
The role of inflammation is particularly relevant. The CANTOS trial (which used the IL-1-beta antibody canakinumab, not a GLP-1RA) proved that reducing inflammation alone, without affecting cholesterol, glucose, or weight, prevents cardiovascular events. GLP-1RAs achieve inflammation reduction through a different mechanism (GLP-1 receptor activation rather than direct cytokine blockade) but converge on the same downstream result: less arterial inflammation, more stable plaques, fewer events. For more on GLP-1-related blood pressure effects, see do GLP-1 agonists lower blood pressure?.
Limitations of the Current Evidence
The antiatherosclerotic case for GLP-1RAs is strong but incomplete.
Most mechanistic data comes from animal models and cell culture. The specific mechanisms identified by Park et al. (2024), including foam cell inhibition, macrophage polarization, and smooth muscle regulation, have been demonstrated primarily in rodent models of atherosclerosis and in vitro endothelial cell assays. Translating these to human coronary atherosclerosis requires assumptions about receptor expression, drug concentrations at the vessel wall, and relevance of the animal models used.
Imaging evidence remains limited. The Rizzo 2014 CIMT study was a small, uncontrolled pilot. Larger randomized trials measuring plaque volume or composition changes with serial imaging have not shown consistent effects across all GLP-1RAs. Exenatide, for instance, did not significantly reduce carotid plaque volume in one trial, though it showed reduced MACE in EXSCEL.
The contribution of individual risk factor improvements is difficult to isolate. GLP-1RAs simultaneously improve glucose, weight, blood pressure, lipids, and inflammation. Disentangling the contribution of each to the overall cardiovascular benefit is statistically challenging, even with mediation analyses.
Not all GLP-1RAs show the same magnitude of benefit. ELIXA (lixisenatide) and EXSCEL (exenatide) achieved noninferiority but not superiority for MACE reduction. This heterogeneity within the class suggests that drug-specific properties (half-life, receptor binding kinetics, tissue penetration) may matter beyond the shared GLP-1 receptor agonism. For a detailed analysis of the SELECT trial, see the SELECT trial: how semaglutide reduced heart attacks and strokes. For how tirzepatide's dual mechanism may affect heart failure outcomes, see tirzepatide SUMMIT: heart failure results in obese patients.
The Bottom Line
GLP-1 receptor agonists reduce atherosclerotic cardiovascular events by 12-26% across multiple large trials, with benefits extending to patients without diabetes. The mechanism appears to involve direct antiatherosclerotic effects: endothelial protection, NF-kB and inflammasome suppression, foam cell inhibition, M2 macrophage polarization, and plaque stabilization. Imaging studies support plaque regression, though large-scale definitive trials are still needed. The consistency of cardiovascular benefit across the class, combined with preclinical mechanistic evidence, establishes GLP-1RAs as genuinely antiatherosclerotic drugs, not merely metabolic agents with incidental cardiovascular effects.